Pathophysiology
Podocyte injury from minimal change (children), FSGS, membranous, diabetic or amyloid; PLA2R antibodies in ~70% primary membranous.
Sources: KDIGO Glomerular Diseases 2021; NEJM PLA2R 2009;361:11
Presentation
Frothy urine, periorbital and dependent oedema, weight gain, hyperlipidaemia, hypercoagulability with renal vein thrombosis risk.
Diagnosis
24-h urine protein or spot UPCR >3.5, hypoalbuminaemia <3 g/dL, serologies (ANA, hepatitis, PLA2R), kidney biopsy in adults.
Management
ACEi/ARB reduce proteinuria; sodium restriction; loop diuretic for oedema; statin; anticoagulation if albumin <2.5 with membranous. Specific therapy: steroids for minimal change; rituximab or tacrolimus for membranous.



